Citicoline as Neuroprotector in Neonates Exposed to Hypoxia
Recruiting
Phase 3
Interventional Study
Neonatal Hypoxia
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- Up to 1 Month
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 40 (estimated)
- Sponsor
- Sherief Abd-Elsalam · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Citicoline as neuroprotector in neonates exposed to hypoxia: A randomized controlled trial
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* neonates with hypoxia.
Exclusion Criteria:
* hypoxic ischemic encephalopathy
Contacts